2026 ICD-10-CM Diagnosis Code T44.7X5AAdverse effect of beta-adrenoreceptor antagonists, initial encounter
T44.7X5A is a billable ICD-10-CM diagnosis code for adverse effect of beta-adrenoreceptor antagonists, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 917 through 918. The code is not accepted as a principal diagnosis by the Medicare Code Editor. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Adverse effects of drugs and medicaments, initial encounter.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T44.7X5A.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Acebutolol adverse reaction
- Adverse reaction caused by metoprolol succinate
- Adverse reaction caused by metoprolol tartrate
- Adverse reaction to nebivolol
- Atenolol adverse reaction
- Beta-adrenoceptor blocking drug adverse reaction
- Betaxolol adverse reaction
- Bisoprolol adverse reaction
- Cardioselective beta-blocker adverse reaction
- Carteolol adverse reaction
- Carvedilol adverse reaction
- Celiprolol adverse reaction
- Class II antiarrhythmic adverse reaction
- Class III antiarrhythmic adverse reaction
- Esmolol adverse reaction
- Metoprolol adverse reaction
- Nadolol adverse reaction
- Oxprenolol adverse reaction
- Penbutolol adverse reaction
- Pindolol adverse reaction
- Practolol adverse reaction
- Propranolol adverse reaction
- Sotalol adverse reaction
- Timolol adverse reaction
Coding GuidelinesGuidance
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system (T44). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Acebutolol
a cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. the drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.Alprenolol
one of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.Atenolol
a cardioselective beta-1 adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect.Betaxolol
a cardioselective beta-1-adrenergic antagonist with no partial agonist activity.Bisoprolol
a cardioselective beta-1 adrenergic blocker. it is effective in the management of hypertension and angina pectoris.Bupranolol
an adrenergic-beta-2 antagonist that has been used for cardiac arrhythmia, angina pectoris, hypertension, glaucoma, and as an antithrombotic.Carteolol
a beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.Celiprolol
a cardioselective beta-1 adrenergic antagonist that has intrinsic sympathomimetic activity. it is used in the management of angina pectoris and hypertension.Metoprolol
a selective adrenergic beta-1 blocking agent that is commonly used to treat angina pectoris; hypertension; and cardiac arrhythmias.Nadolol
a non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. nadolol is also used for migraine disorders and for tremor.Oxprenolol
a beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.Penbutolol
a nonselective beta-blocker used as an antihypertensive and an antianginal agent.Pindolol
a moderately lipophilic beta blocker (adrenergic beta-antagonists). it is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (from martindale, the extra pharmocopoeia, 30th ed, p638)Practolol
a beta-1 adrenergic antagonist that has been used in the emergency treatment of cardiac arrythmias.Propranolol
a widely used non-cardioselective beta-adrenergic antagonist. propranolol has been used for myocardial infarction; arrhythmia; angina pectoris; hypertension; hyperthyroidism; migraine; pheochromocytoma; and anxiety but adverse effects instigate replacement by newer drugs.Sotalol
an adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.Timolol
a beta-adrenergic antagonist that is similar in action to propranolol; the levo-isomer is more active. timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. it is also used in the treatment of migraine disorders and tremor.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T44.7X5A to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T44.7X5AOverview
Is T44.7X5A (Adverse effect of beta-adrenoreceptor antagonists) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of beta-adrenoreceptor antagonists, initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character A in T44.7X5A mean?
The final character A marks the initial encounter: use it while the patient is receiving active treatment for adverse effect of beta-adrenoreceptor antagonists, such as an emergency visit or first evaluation.
What MS-DRG does T44.7X5A group to?
On inpatient claims, adverse effect of beta-adrenoreceptor antagonists, initial encounter maps to MS-DRG 917, 918, with relative weights from 0.8571 to 1.5684 depending on complications. Higher weights mean higher Medicare reimbursement.
Can T44.7X5A be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of beta-adrenoreceptor antagonists, initial encounter describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
What is the ICD-9 equivalent of T44.7X5A?
Under the General Equivalence Mappings, adverse effect of beta-adrenoreceptor antagonists, initial encounter converts to ICD-9-CM 995.29 (adv eff med/biol NEC/NOS) and E941.3 (adv eff sympatholytics). The mapping is approximate, so confirm the match fits the documentation.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
